Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Strengthening India’s Global Pharma Leadership: Why the 15th IMWP matters
Union Minister of State for Health & Family Welfare, Smt. Anupriya Patel reaffirmed India’s commitment to pharmaceutical standardization, regulatory convergence, and ensuring global access to high-quality medicines. The meeting served as a crucial platform for international cooperation, addressing evolving regulatory frameworks, impurity assessment standards, and sustainability in pharmaceutical manufacturing.
- By Pooja Chaturvedi Sah
- New Delhi
- Feb 07, 2025
The 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare, Government of India, in collaboration with the World Health Organization (WHO), underscored India’s pivotal role in shaping global pharmaceutical standards.
The event, held in New Delhi on 5 February, brought together international pharmacopoeial authorities, regulatory bodies, and industry leaders to discuss harmonization, emerging challenges in drug quality, and the future of pharmaceutical standard-setting.
Union Minister of State for Health & Family Welfare, Smt. Anupriya Patel, delivered the keynote address, reaffirming India’s commitment to pharmaceutical standardization, regulatory convergence, and ensuring global access to high-quality medicines. The meeting served as a crucial platform for international cooperation, addressing evolving regulatory frameworks, impurity assessment standards, and sustainability in pharmaceutical manufacturing.
India’s Growing Influence in Global Pharma Standards
As the world’s third-largest pharmaceutical producer by volume, India plays a critical role in supplying affordable medicines to global markets.
Recognized as the “Pharmacy of the World,” the country has been at the forefront of ensuring quality, safety, and efficacy in drug manufacturing. At the IMWP, India reaffirmed its leadership in pharmacopoeial science, with IPC showcasing initiatives such as the IP Online platform—a digital tool enhancing accessibility to Indian Pharmacopoeia standards.
“IMWP serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization,” stated Patel. “As the ‘Pharmacy of the World,’ India is committed to ensuring global access to high-quality medicines and aligning with international best practices”, she added.
Regulatory experts and industry leaders discussed the importance of global harmonization, emphasizing how aligning with international best practices can accelerate drug approvals, streamline regulatory processes, and expand market access for Indian pharmaceutical firms.
Smt. Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, emphasized the importance of global partnerships in strengthening pharmaceutical quality standards. “India is actively working towards aligning regulatory frameworks with international standards to ensure the availability of safe and effective medicines worldwide,” she said.
Dr. Rajeev Singh Raghuvanshi, Drugs Controller General (India) and IPC Secretary-cum-Scientific Director, highlighted IPC’s contributions to global standard-setting. He emphasized scientific advancements and regulatory cooperation as key drivers in shaping the future of pharmaceutical regulations. “India is setting global benchmarks in pharmaceutical standardization. Our IP Online platform enhances accessibility to Indian Pharmacopoeia standards, ensuring compliance and ease of use for industry stakeholders,” he noted.
Why the IMWP Matters for Indian Pharma & Healthcare
1. Strengthening India’s Global Pharma Footprint
India’s role in regulatory convergence and harmonization is increasingly recognized worldwide. By aligning with international pharmacopoeial standards, Indian pharma companies can enhance their credibility, meet stringent regulatory requirements, and expand their presence in high-value markets like the US, Europe, and Japan.
2. Regulatory Harmonization: A Pathway to Easier Global Market Access
The IMWP highlighted progress on harmonization initiatives, including updates from the Pharmacopoeial Discussion Group (PDG). Aligning with ICH Q6 guidelines on impurity assessment is crucial for Indian manufacturers, as non-compliance can hinder exports. Regulatory standardization reduces duplication of efforts, streamlining approval processes for Indian drugs in multiple markets.
3. Digital Transformation in Pharma Quality Standards
IPC’s IP Online platform was a key focus area, highlighting the growing need for digital tools in compliance and quality assurance. With global pharmacopoeias adopting digital frameworks, Indian pharmaceutical firms must leverage digital transformation to stay competitive.
4. Addressing Impurity Challenges & Ensuring Compliance
Discussions on emerging impurity assessment challenges (Q3) and ICH Q6 guidelines underscored the need for advanced analytical techniques and stringent compliance measures. Indian pharma companies must adapt to these evolving standards to maintain product quality and regulatory approvals.
5. Sustainability in Pharmaceutical Manufacturing
The IMWP also emphasized environmental sustainability in pharmacopoeial practices. As global regulations tighten on green chemistry, waste reduction, and eco-friendly drug production, Indian pharma leaders must proactively adopt sustainable manufacturing processes to maintain regulatory approvals and enhance global competitiveness.
The Road Ahead
The outcomes of the 15th IMWP hold the potential to influence the future policies of India’s pharma industry; everything from drug approvals and export programmes to pharmacopoeial standardization and digital transformation.
With the next IMWP discussions already in the pipeline, Indian regulators, policymakers, and industry leaders were called to take proactive steps to integrate global standards, invest in digital quality frameworks, and prioritize sustainability.
As India cements its status as a trusted global supplier of high-quality medicines, embracing international pharmacopoeial cooperation and cutting-edge regulatory frameworks will be key to securing its leadership in the evolving pharmaceutical landscape.